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Background: Myocardial fibrosis (MF) is a risk factor for poor prognosis in dilated
cardiomyopathy (DCM). Late gadolinium enhancement (LGE) of the myocardium on
cardiac magnetic resonance (CMR) represents MF. We examined whether the LGE
amount increases the incidence of adverse cardiovascular events in patients with stage
C or D heart failure (HF).
Methods: Eighty-four consecutive patients with stage C or D HF, either ischemic
or non-ischemic, were enrolled. Comprehensive clinical and CMR evaluations were
performed. All patients were followed up for a composite endpoint of cardiovascular
death, heart transplantation, and cardiac resynchronization therapy with defibrillator
(CRT-D).
Results: LGE was present in 79.7% of the end-stage HF patients. LGE distribution
patterns were mid-wall, epi-myocardial, endo-myocardial, and the morphological
patterns were patchy, transmural, and diffuse. During the average follow-up of 544 days,
13 (15.5%) patients had endpoint events: 7 patients cardiac death, 2 patients heart
transplantation, and 4 patients underwent CRT-D implantation. On univariate analysis,
LGE quantification on cardiac magnetic resonance, blood urine nitrogen, QRS duration
on electrocardiogram, left ventricular end-diastolic diameter (LVEDD), and left ventricular
end-diastolic volume (LVEDV) on CMR had the strongest associations with the composite
endpoint events. However, on multivariate analysis for both Model I (after adjusting for
age, sex, and body mass index) and Model II (after adjusting for age, sex, BMI, renal
function, QRS duration, and atrial fibrillation on electrocardiogram, the etiology of HF,
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LVEF, CMR-LVEDD, and CMR-LVEDV), LGE amount was a significant risk factor for
composite endpoint events (Model I 6SD HR 1.037, 95%CI 1.005–1.071, p = 0.022;
Model II 6SD HR 1.045, 95%CI 1.001–1.084, p = 0.022).
Conclusion: LGE amount from high-scale threshold on CMR increased the incidence
of adverse cardiovascular events for patients in either stage C or D HF.
Keywords: heart failure, magnetic resonance imaging, late gadolinium enhancement, prognosis, adverse
cardiovascular events
INTRODUCTION
End-stage heart failure is associated with significant morbidity
and mortality (Adams et al., 1996; Bart et al., 1997). To improve
the prognosis, the optimal therapeutic strategies for patients with
end-stage heart failure currently include cardioverter defibrillator
implantation (ICD), cardiac resynchronization therapy (CRT),
ventricular assist devices implantation (Anand et al., 2015), and
heart transplantation (Yancy et al., 2013). Complex invasive
therapeutic decisions for patients with stage C or D heart failure
are mainly guided by left ventricular ejection fraction (LVEF;
Epstein et al., 2013; Yancy et al., 2013). However, using LVEF as a
parameter to identify eligible patients has a number of limitations
(Gulati et al., 2013). Identifying the optimal prognosis factors for
patients with end-stage heart failure remains a challenge.
The most common cause of end-stage heart failure
includes ischemia-dilated cardiomyopathy (IDCM) and
non-ischemia-dilated cardiomyopathy (NIDCM; Sisakian,
2014). Histologically, the main feature of end-stage damaged
myocardium, whether ischemic or non-ischemic, is the
development of interstitial and replacement fibrosis that varies in
severity (Schaper et al., 1991; Yarbrough et al., 2012). Expansion
of the extracellular matrix, which is observed in individuals with
myocardial fibrosis, is associated with contractile impairment
(Baig et al., 1998; Mann and Bristow, 2005) and provides
a substrate for ventricular reentrant arrhythmia (Hsia and
Marchlinski, 2002; Iles et al., 2011), which represents a strong
risk factor for adverse cardiac outcomes (Assomull et al., 2006).
Late gadolinium enhancement from cardiac magnetic resonance
(LGE-CMR) is capable of detecting tissue abnormalities,
particularly myocardial fibrosis (Nanjo et al., 2009). Researchers
recently discovered that, in addition to LVEF, late gadolinium
enhancement (LGE) could be used as a marker of poor prognosis
in patients with NIDCM (Gulati et al., 2013; Neilan et al., 2013;
Kuruvilla et al., 2014; Perazzolo Marra et al., 2014; Pöyhönen
et al., 2014). However, little is known about the role of LGE
quantification for patients with stage C or D heart failure; in
addition, controversy persists regarding LGE amount and its
prognostic value (Neilan et al., 2013; Perazzolo Marra et al.,
2014).
Here, we aimed to assess the association between LGE-CMR
quantification and the prognosis of patients with stage C or
D heart failure. We hypothesized that LGE-CMR amount is
associated with a higher risk of adverse cardiac outcomes in
patients with stage C or D heart failure regardless of ischemic or
non-ischemic etiology.
MATERIALS AND METHODS
The Department of Heart Failure Program at Anzhen
Hospital (Capital Medical University of Beijing, China)
performed a prospective observational cohort study. The
study enrolled 84 consecutive heart failure patients between
January 1st, 2014 and December 31st, 2014, with ischemic
or non-ischemic heart disease as defined by the World
Health Organization/International Society and the Federation
of Cardiology criteria (Richardson et al., 1996). Inclusion
criteria included: stage C or D heart failure (Jessup et al.,
2009; Chen-Scarabelli et al., 2015), ischemic or non-ischemic
cardiomyopathy (IDCM and NIDCM), LVEF <40%, and
left ventricular end-diastolic diameter (LVEDD) >60 mm
on echocardiography. Patients with valvular heart disease,
congenital heart disease, infiltrative cardiomyopathy (i.e.,
sarcoidosis and amyloidosis), renal failure, acute myocardial
infarction (AMI) within 1 month, poor compliance, or a
history of CRT and ICD implantation were excluded from
the study. All patients enrolled in the study underwent a
comprehensive clinical evaluation, coronary angiography, and
MRI. Ischemic dilated cardiomyopathy was diagnosed when
coronary angiography showed >50% narrowing of the coronary
artery lumen or when the patient had a history of MI. Non-
ischemic dilated cardiomyopathy may have been idiopathic,
familial/genetic, viral, immune, or alcoholic/toxic (Richardson
et al., 1996). Patients enrolled in the study provided written
informed consent. The protocol was approved by the Human
Subjects Review Committee at Anzhen Hospital (Approval No.
2013007X). All of the experiments were performed in accordance
with relevant guidelines and regulations.
All cardiac magnetic resonance (CMR) examinations were
performed using a 3.0-T Magnetic Resonance Imaging (MRI)
system (Verio, Siemens Medical Solutions, Erlangen, Germany)
with a 32-channel phased-array coil. True fast imaging with
steady state free precession breath-hold cine images were
acquired in the short-axis, and 2-, 3-, and 4-chamber views
encompassing the entire left ventricle (LV) volume from the apex
to the base. Diastolic phase myocardial delayed enhancement
images in the same orientations as in the cine images were
acquired 10 min after intravenous infusion with gadolinium
chelate contrast agent (Magnevist, Bayer Schering, Germany,
0.2 mmol/kg) with a prospectively ECG-gated gradient echo
sequence with an inversion prepulse. Inversion times were
optimized to null normal myocardium. Imaging parameters were
as follows: repetition time/echo time, 4.1/1.6ms; flip angle, 20◦;
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image matrix, 256 × 130; section thickness, 8mm (contiguous
short axis) or 5mm (long axis images), with no intersection gap.
The QMASS commercial software package (Medis,
Netherland) was used to analyze the CMR DICOM images.
The cardiac functional indexes, specifically the left ventricular
ejection fraction (LVEF), volumes, and mass were quantified
from cine images by using standard methods. The volume
and mass of the LV was normalized to the body surface area.
Two experienced observers, blinded to the clinical outcome
independently determined the dichotomous presence or absence
of LGE by reviewing all short and long axis contrast-enhanced
images; regions of elevated signal intensity had to be confirmed
in two spatial orientations. Once the LGE was present, the
distribution of the LGE was recorded in the 17 segments
according to the standards of the American Heart Association
(AHA). Furthermore, the quantity of hyper-enhancement was
defined as regions with an abnormally increased signal intensity
>2SD and >6SD of the peak remote. According to other
studies (Flett et al., 2011; Maron, 2013; Moravsky et al., 2013;
Chan et al., 2014) as well as the characteristics of our study
population, the high gray-scale threshold (6SD) as the LGE
quantification method was mainly used here. For each short
axis cross-section, after the endocardial and epi-cardial borders
were traced, a region of interest (ROI) averaging 50mm2 was
defined within the normal remote myocardium, in an area
with uniform myocardial suppression, free of artifacts. The
commercial software automatically calculated the %Myo (LGE
positive volume/Total myocardium volume× 100%).
Follow-up was performed until January of 2016. The patients
were followed-up for major adverse cardiac events (MACE),
including cardiovascular death, cardiac transplantation, and
cardiac resynchronization therapy with defibrillator (CRT-
D). CRT-D implantation was based on information obtained
from medical records and telephone calls. CRT-Ds were only
implanted in patients who fit the guideline recommendation
criteria for CRT-Ds and who had recurrent admissions for heart
failure, despite undergoing at least 6 months of optimal medical
therapy (Yancy et al., 2013).
Continuous variables are expressed as mean ± standard
deviations (SD), while categorical variables are expressed as a
frequency (%). Continuous variables were compared using an
unpaired Student t-test or a Mann-Whitney nonparametric test,
as appropriate. Categorical variables were performed using the
Pearson Chi-Square test and the Fisher exact test. A P < 0.05
was deemed statistically significant and all statistical tests
were 2-sided. Receiver operating characteristic (ROC) curves
constructed using Bootstrap resampling (times = 500) were
used to find the optimal cut-off values for LGE quantification
(with maximizing the sum of sensitivity and specificity) as
measured by 6SD methods to predict MACE. Survival estimates
and cumulative event rates were compared by the Kaplan–
Meier method by using the time-to-first event for each
endpoint. The log-rank test was used to compare the Kaplan–
Meier survival curves. Cox regression analyses were used to
estimate the hazard ratio (HR) for adverse events and their
corresponding 95% confidence intervals (CI). Univariate Cox
regression analyses were used to examine all significant variables.
We also adjusted for variables that, when added to this model,
changed the Matched Hazard Ratio by at least 10%. All analyses
were performed using Empower (R) (http://www.empowerstats.
com, X&Y solutions, Inc., Boston MA) and R (http://www.R-
project.org).
RESULTS
Of the 84 patients with either ischemic or non-ischemic
heart failure, the average age was 52 years (51.5 ± 12.3)
at the time of CMR imaging, in addition, 65 of the these
patients (77.4%) were male. The mean LVEF on CMR was
16.4 ± 8.8%, and all patients at presentation had either stage
C or stage D heart failure. After extensive cardiac examination
of all patients at baseline, 57 patients (67.9%) were diagnosed
with non-ischemic dilated cardiomyopathy, and 27 patients
(32.1%) were diagnosed with ischemic dilated cardiomyopathy,
and atrial fibrillation was observed on the electrocardiogram
among 20.5% of patients with heart failure, Table 1. Among
the entire cohort, 95% were prescribed either an angiotensin-
converting enzyme inhibitor or an angiotensin II receptor
blocker, 95%were prescribed a beta-blocker, 94%were prescribed
an aldosterone antagonist, until then, 96.5% were prescribed loop
diuretics.
LGE was present in 67 patients (79.76%). LGE distribution
pattern was mid-wall and epi-myocardial in 24 (35.8%, 24/67)
patients, endo-myocardium in 12 (17.9%, 12/67) patients, patchy
in 6 (9.0%, 6/67) patients, transmural in 20 (29.9%, 20/67)
patients, and diffuse in 5 (7.5%, 5/67) patients (Figure 1). The
involved myocardial segments listed in the Figure 2, based on
the all study patients discriminated with the ischemic and non-
ischemic etiology (IDCM and NIDCM) of heart failure. The
average volume of LGE, expressed as a percentage of the total
LV volume by using the 2SD & 6SD methods, was significantly
greater in patients with events than in those with no events
(LGE 2SD %Myo: 58.5 ± 6.55 vs. 36.9 ± 2.24; LGE 6SD %Myo:
21.6 ± 6.16 vs. 6.1 ± 1.26 in events patients vs. free-event
patients, respectively; p < 0.001). However, although the LVEF
on CMR was lower in patients with events, these differences were
not statistically significant (13.2± 2.36 vs. 17.0± 1.04% p= 0.16;
Figure 3).
During the average 544 days follow-up period (min 365
days and max 673 days), 13 (15.5%) patients developed major
adverse cardiac events; in addition, 7 patients died, 2 patients
underwent cardiac transplantation, and 4 patients underwent
CRT-D implantation.
The results of the univariate analyses of major adverse
events during the follow-up period are summarized in Table 2.
Univariate analyses showed that the widened QRS duration on
EKG, and the renal function, the amount of LV-LGE, LVEDD,
and left ventricular end-diastolic volume (LVEDV) on CMR
were associated with significant increases in the incidence of
adverse cardiovascular events. However, the predicted value of
LVEF on CMR was not significantly different (HR 0.956; 95%CI
0.878–1.041; P = 0.305). In the multivariable analysis shown
in Table 3, the amount of LV-LGE was the only independent
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TABLE 1 | Baseline characteristics of patients with stage C&D heart failure.
All patients (n = 84) Event-free patients (n = 71) Event patients (n = 13) P
Age, mean (SD) (years) 51.5 ± 12.3 50.6 ± 12.4 56.8 ± 10.5 0.096
Male (%) 65 (77.38%) 54 (76.1%) 11 (84.6%) 0.498
BMI, mean (SD) (kg/m2) 26.7 ± 4.3 26.8 ± 4.2 25.8 ± 4.6 0.450
Etiology of heart failure 0.596
IDCM (%) 27 (32.1%) 22 (31.0%) 5 (38.5%)
NIDCM (%) 57 (67.9%) 49 (69.0%) 8 (61.5%)
SBP, mean (SD) (mmHg) 113.1 ± 15.08 114.4 ± 14.9 106.2 ± 14.7 0.069
Atrial fibrillation (%) 17 (20.5%) 12 (17.1%) 5 (38.5%) 0.08
hs-CRP mean (SD) (mg/L) 6.7 ± 8.6 6.4 ± 8.4 7.9 ± 9.7 0.565
BUN mean (SD) (mmol/L) 7.4 ± 1.9 7.2 ± 1.7 8.7 ± 2.7 0.009
MEDICATION
ACEI/ARB (%) 80 (95.2%) 69 (97.2%) 11 (84.6%) 0.875
Beta-blocker (%) 80 (95.2%) 68 (95.8%) 12 (92.3%) 0.589
Spironolactone (%) 79 (94.1%) 68 (95.8%) 11 (84.6%) 0.118
Diuretics (%) 81 (96.4%) 69 (97.2%) 12 (92.3%) 0.384
QRS duration mean (SD) (mm) 137.2 ± 36.0 132.5 ± 31.3 162.5 ± 49.2 0.005
CMR CHARACTERISTICS
CMR-LVEDD, mean (SD) (mm) 70.9 ± 9.7 70.2 ± 8.8 75.0 ± 13.3 0.101
CMR-EF, mean (SD) 16.4 ± 8.8 17.0 ± 8.8 13.2 ± 8.5 0.160
CMR-LVEDV, mean (SD) (ml) 279.8 ± 103.9 265.5 ± 84.7 357.8 ± 158.1 0.003
LGE 2SD%Myo, mean (SD) 40.3 ± 21.1 36.9 ± 18.9 58.5 ± 23.6 <0.001
LGE 6SD%Myo, mean (SD) 8.5 ± 14.1 6.1 ± 10.6 21.6 ± 22.2 <0.001
IDCM, ischemic dilated cardiomyopathy; NIDCM, non-ischemic dilated cardiomyopathy; BMI, Body mass index; SBP, systolic blood pressure; hs-CRP, hypersensitive C-reactive protein;
BUN, blood urea nitrogen; ACEI/ARB, angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker; LVEDD, left ventricular end-diastolic diameter, EF ejection fraction;
LVEDV, left ventricular end diastolic volume; SD, standard deviation.
risk factor for major adverse events in Model I (HRadj 1.44/10%
increase in 6SD %Myo, 95%CI 1.05–1.98, P = 0.022) after
adjusting for the patients’ age, sex, and body mass index (BMI),
and in Model II (HRadj 1.54/10% increase in 6SD %Myo, 95%CI
1.06–2.24, P = 0.022) after adjusting for patients’ age, BMI, sex,
blood urea nitrogen (BUN), QRS duration, and Atrial fibrillation
(%) on EKG, etiology of heart failure, LVEF, CMR- LVEDD, and
LVEDV.
ROC curves of LGE quantification were used to determine the
optimal cut-off values for prediction of events during follow-up
by using a bootstrap resampling (times = 500) showed an area
under curve of 0.74 (95%CI 0.58–0.89; Figure 4). The best cut
point based on maximizing the sum of sensitivity and specificity
for 6SD method was 10.91% (sensitivity: 61.5%; specificity:
85.9%). Kaplan–Meier survival analysis (Figure 5) showed a
significant difference between patients stratified by the amount
of LGE, that the extent of LGE of >10.91 or <10.91% of the
volume of the left ventricle, as measured using the 6SD method
(Log-rank, P < 0.001).
DISCUSSION
Heart failure is a serious condition that constitutes medical
and financial burdens in developed and developing countries.
Approximately half of all patients with heart failure die within
5 years after receiving the diagnosis, which is worse than that for
many cancers (Katz, 1990). The most common cause of clinical
heart failure is dilated cardiomyopathy, which is ischemic or non-
ischemic in etiology, and associated with high morbidity and
mortality (Hunt et al., 2005; Maron et al., 2006).
Histologically, the end-stage damaged myocardium is
characterized by a diverse abnormal myocardial substrate
including reparative (replacement) and reactive (interstitial and
perivascular) fibrosis, leading to expanded extracellular matrix
(de Leeuw et al., 2001). LGE can be used to non-invasively
identify of myocardial fibrosis. Researchers also discovered that
LGE could be used as a marker of poor prognosis in patients
with NIDCM (Gulati et al., 2013; Neilan et al., 2013; Kuruvilla
et al., 2014; Perazzolo Marra et al., 2014) and HCM (Chan et al.,
2014). However, the current LGE cannot differentiate between
interstitial and replacement fibrosis (Moravsky et al., 2013),
and consensus is lacking about how to quantify LGE in patients
with stage C or D heart failure. There are several quantitative
techniques for LGE, including a gray-scale threshold a number
of SDs above the mean signal intensity within a remote region
containing normal “nulled” myocardium (i.e., 2, 4, 5, or 6SD) and
the full width at half maximum (FWHM) method (Flett et al.,
2011; Maron, 2013; Moravsky et al., 2013; Contaldi et al., 2016).
Moravsky et al. (2013) first provided an evaluation correlating
histological findings with a variety of LGE quantification
methods in patients with HCM. Their study discovered
(Maron, 2013) that a high gray-scale threshold provided a
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FIGURE 1 | Different patterns and distributions of LGE in patients with end-stage heart failure. The first panel shows the four-chamber view of the heart, the
second panel displayed the patterns of LGE. The 2SD and 6SD algorithm quantitative assessments of myocardial fibrosis are marked in the third and fourth panels.
Rows A through E depict mid-wall, endo-myocardial, transmural, diffuse, and patchy enhancements in the short axis. LGE, late gadolinium enhancement; SD,
standard deviation.
better representation of total fibrosis burden (interstitial and
replacement fibrosis) than the lower thresholds and the FWHM
method. Considering the diverse histopathological abnormalities
including interstitial and replacement fibrosis in end-stage heart
failure patients (de Leeuw et al., 2001), the high gray-scale
threshold (6SD) as the LGE quantification method was used
here. Our study was designed to evaluate the correlation between
the amount of LGE (6SD) on CMR and major adverse events
in a large population of patients with stage C or D heart failure
and dilated cardiomyopathy despite ischemic or non-ischemic
etiology.
The major finding of our study was that the amount of LGE
from high-scale threshold on CMR increased the likelihood for
adverse cardiovascular outcomes in patients with stage C or
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FIGURE 2 | The distribution of LGE in individual myocardial segments in all LGE positive patients (blue bars), in patients with IDCM (green bars), and in
patients with NIDCM (red bars). The diagram demonstrates that LGE in patients with NIDCM occurs most commonly in the septal wall of the left ventricle while
LGE in patients with IDCM commonly involves the coronary artery dominated area. IDCM, ischemia-dilated cardiomyopathy; LGE, late gadolinium enhancement;
NICD, non-ischemia-dilated cardiomyopathy.
stage D heart failure. This association was independent of the
LVEF and the etiology of heart failure (IDCM and NIDCM;
Tables 2, 3). Using multivariable Cox regression analysis, we
determined that the adjusted HRs for patients with stage C or
stage D heart failure with 6SD %Myo were 1.037 (P = 0.022), in
Model I, and 1.045 (P = 0.022) in Model II for cardiovascular
death and cardiac transplantation or implanted CRT-D. Our
results also indicated that LGE cutoff values of 10.91% (6SD
method) for patients with stage C or stage D heart failure are
associated with poor outcomes.
The CMR LGE patterns and distributions in our cohort
study are consistent with those reported in prior pathologic
studies of NIDCM (Assomull et al., 2006; Wu et al., 2008;
Gulati et al., 2013), which involved the mid-myocardium of
the septal wall (Figure 2). However, the delayed enhancement
in IDCM tends to occur in the endocardium or transmural
region and follows a vascular distribution. The pathophysiology
underlying CMR abnormalities is uncertain since dilated
cardiomyopathy is the final common pathway for presumably
multiple etiologies. Myocardial fibrosis in end-stage heart
failure is due to activation of the circulating renin-angiotensin
system (RAS) and aldosterone production that eventually lead
to progressive myocyte dysfunction, apoptosis, and fibroblast
hyperplasia (Swynghedauw, 1999).
Perazzolo Marra et al. (2014) evaluated the impact
of myocardial fibrosis presence and amount on NIDCM
prediction. Their study showed that LV-LGE was a powerful
and independent predictor of prognosis, while the amount of
LGE and its distribution did not provide additional prognostic
value. Conversely, in our cohort study, there was a strong
association between the amount of LGE and poor prognosis.
This difference may be due to differences in the study population.
In our study, all patients had obvious symptoms of stage C or D
heart failure. Myocardial fibrosis is common in these patients.
Accordingly, the percentage of patients with LGE (79.76%) in
our study was significantly higher than reported by previous
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FIGURE 3 | The diagram displays statistical differences in %Myo of
LGE for both 2-SD and 6-SD algorithms (mean ± SE, P < 0.001) in
patients with and without events. No statistical difference in conventional
cardiac ejection function index (mean ± SE, P = 0.16) is detected. LGE, late
gadolinium enhancement; SD, standard deviation.
TABLE 2 | Univariate analysis for major adverse events in patients with
stage C or stage D heart failure during follow-up.
Variable No. of event/No. of
participants (%)
HR 95% CI P-value
Age (years) 13/84 (15.47) 1.043 0.995–1.094 0.082
SEX
Female 2/19 (10.52) Ref – –
Male 11/65 (16.92) 2.359 0.503–11.058 0.276
BMI (kg/m2) 13/84 (15.47) 0.970 0.852–1.104 0.647
ETIOLOGY OF HF
IDCM 5/27 (18.51) Ref – –
NIDCM 8/57 (14.04) 0.823 0.267–2.534 0.734
HEART RHYTHM
Sinus rhythm 8/66 (12.12) Ref – –
Atrial fibrillation 5/17 (29.41) 2.145 0.678–6.789 0.194
BUN (mmol/L) 13/84 (15.47) 1.344 1.068–1.692 0.012
QRS duration (mm) 13/84 (15.47) 1.015 1.001–1.029 0.039
CMR-LVEDD (mm) 13/84 (15.47) 1.078 1.023–1.135 0.005
CMR-LVEDV (ml) 13/84 (15.47) 1.006 1.002–1.010 0.002
CMR-LVEF 13/84 (15.47) 0.956 0.878–1.041 0.305
2SD %Myo 13/84 (15.47) 1.034 1.011–1.057 0.003
6SD %Myo 13/84 (15.47) 1.028 1.005–1.051 0.016
BMI, body mass index; BUN, blood urine nitrogen; CI, confidence interval; CMR-
LVEDD, cardiac magnetic resonance left ventricular end-diastolic diameter; CMR-LVEDV,
cardiac magnetic resonance left ventricular end-diastolic volume; HR, hazard ratio;
IDCM, ischemic cardiomyopathy; NIDCM, non-ischemic cardiomyopathy; SD, standard
deviation, %Myo, LGE positive volume/Total myocardium volume × 100%.
studies (Perazzolo Marra et al., 2014). Although the current
LGE cannot differentiate interstitial and replacement fibrosis
(Moravsky et al., 2013), it can provide a total fibrosis burden
(interstitial and replacement fibrosis; Maron, 2013). This kind
TABLE 3 | Multivariate analysis with LGE-CMR quantification for major
adverse events in patients with Stage C or D heart failure during follow-up.
Model I Model II
HR 95% CI P-value HR 95% CI P-value
6SD %Myo
per 1% increase
1.037 1.005–1.071 0.022 1.045 1.001–1.084 0.022
6SD %Myo
per 10% increase
1.44 1.053–1.982 0.022 1.546 1.065–2.244 0.022
Model I adjust for: age, sex, BMI. Model II adjust for: age, sex, BMI, BUN, QRS duration
on EKG, Atrial fibrillation (%), etiology of heart failure, LVEF, CMR-LVEDD, CMR-LVEDV.
SD, standard deviation; HR, hazard ratio; CI, confidence interval.
FIGURE 4 | ROC curves for the amount of LGE, using Bootstrap
resampling (times = 500) for the association of major adverse cardiac
events. AUC confidence interval and significance tests using Bootstrap
resampling. The best cut point was based on maximizing the sum of sensitivity
and specificity. The analysis reveals that the percentage of LGE by volume of
>10.91%, using the 6-SD method (AUC: 0.74, 95% CI 0.58–0.89; sensitivity:
61.5%; specificity: 85.9%). ROC, receiver-operating characteristic; AUC, area
under the curve; SD, standard deviation; CI, confidence interval.
of histopathological abnormality would lead to an expanded
extracellular matrix (de Leeuw et al., 2001). Chan et al. (2014)
found that extent of LGE was associated with an increased risk
of events (adjusted hazard ratio, 1.46/10% increase in LGE;
P = 0.002). Although the study populations were very different,
the results of patients with hypertrophic cardiomyopathy (HCM)
in their study and those with stage C or D heart failure in our
study were consistent with the results reported by Chan et al.
(2014). Our data also showed that extensive LGE remained an
important marker of an increased risk of major adverse events
(HRadj, 1.54/10% increase in 6SD %Myo, P = 0.022), even after
the adjustment for other relevant variables, including LVEF. The
Bootstrap resampling (times= 500) was used to find the optimal
Frontiers in Physiology | www.frontiersin.org 7 October 2016 | Volume 7 | Article 484
Liu et al. LGE as an Independent Risk Factor for Heart Failure
FIGURE 5 | Kaplan–Meier event-free survival curve. Kaplan–Meier analysis of freedom from major adverse cardiac events according to: LGE of >10.91
or <10.91% of the volume of the left ventricle, as measured using the 6SD method. (Log-rank, P < 0.001). LGE, late gadolinium enhancement; SD, standard deviation.
cut-off value and the 6SD LGE >10.91% of LV mass conferred
the high risk of major adverse events in patients with stage C or
D heart failure.
The current assessment of the prognosis of patients with
stage C or D heart failure, either ischemic or non-ischemic in
etiology, is purely based on a decreased LVEF (Rihal et al.,
1994; Grzybowski et al., 1996), which has been considered
a strong risk factor for mortality. However, although the
mortality in patients with stage C or D heart failure increases
as LVEF decreases, the association is very weak in patients
with severe systolic dysfunction (Dec and Fuster, 1994). Clinical
trials have provided evidence that LVEF and LVEDD can be
reversed by medical therapy (Aleksova et al., 2009). Therefore,
in patients with severe left ventricular systolic impairment,
a prognosis evaluation based on LVEF alone is insufficient.
In the present study, MF quantification provided additional
prognostic value across the entire range of LVEF for all end
points.
In conclusion, the detection of myocardial fibrosis by
measuring LGE from high-scale threshold on CMR increased
poor outcomes for primary endpoints in patients with stage
C or D heart failure with either ischemic or non-ischemic in
etiology. These findings have potentially important implications
which may have applications in the reclassification of patient
groups suitable for device therapy (i.e., CRT-D, transplantation,
left ventricular assist device implantation) with end-stage heart
failure. Further research efforts should include a prospectively
enrolled cohort to determine whether CMR in combination
with other novel markers could help identify patients with stage
C or D heart failure who may benefit from additional device
treatment.
LIMITATIONS
The major limitation of our study is the relatively small cohort
size and short follow-up period. Furthermore, there were only
two cases of heart transplantations in our study. The pathological
report for the recipient’s heart further confirmed our diagnosis
of IDCM and NIDCM. We will continue to follow the study
population to collect additional pathological results in support of
our initial diagnosis. Finally, we quantified LGE using a signal
intensity threshold of 6SD above a remote reference region.
The traditional LGE measurement method cannot detect small
patches as well as diffuse microscopic fibrosis. The T1 mapping
technique may enable us to improve the clinical assessment of
diffuse myocardial fibrosis.
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